SCHEMBL14749285

SCHEMBL14749285

Cc1ccc(-c2cc(C3CCCN(C(=O)Cc4cccc5ccccc45)C3)n(-c3ncccn3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ PRCP P42785 5/20 0.53
▸ MAPK1 P28482 2/20 0.44
▸ SYK P43405 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ APOBEC3A P31941 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ MAP3K12 Q12852 1/20 0.42
▸ PDE2A O00408 3/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12183983 0.92 PRCP (0.64) KMT2AMEN1PRCPMAPK1SYK
SCHEMBL14749287 0.86 PRCP (0.72) KMT2AMEN1PRCPSYKKDM4E
SCHEMBL14686464 0.83 PRCP (0.76) KMT2AMEN1PRCPMAPK1SYK
SCHEMBL14749316 0.83 PRCP (0.57) PRCPMAPK1KDM4EMAP3K12PDE2A
SCHEMBL14749333 0.82 PRCP (0.59) KMT2AMEN1PRCPMAPK1KDM4E
SCHEMBL14749335 0.81 PRCP (0.64) KMT2APRCPKDM4EPDE2A
SCHEMBL14749338 0.80 PRCP (0.65) KMT2APRCPSYKKDM4ESMN1; SMN2
SCHEMBL12184064 0.79 PRCP (0.83) PRCPSYKKDM4ESMN1; SMN2
SCHEMBL14749320 0.78 PRCP (0.58) PRCPMAPK1SYKKDM4EMAP3K12
SCHEMBL14701329 0.77 PRCP (0.86) PRCPSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP KMT2A 2172/4885MEN1 3238/4885PRCP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback